Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting

Abstract This review summarizes the significant advancements in prophylaxis against graft-versus-host disease (GvHD) presented at the 2022 ASH Annual Meeting. The use of innovative agents and regimens, along with the conventional prophylactic approach of combining post-transplant cyclophosphamide an...

Full description

Bibliographic Details
Published in:Experimental Hematology & Oncology
Main Authors: Yiyin Chen, Yang Xu, Depei Wu
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2023
Subjects:
Hematopoietic stem cell transplantation
Graft-versus-host disease
Prophylaxis
Diseases of the blood and blood-forming organs
RC633-647.5
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Orca
Online Access:https://doi.org/10.1186/s40164-023-00425-y
https://doaj.org/article/a152b3b0a90c479a9d30227046186448
Description
Summary:Abstract This review summarizes the significant advancements in prophylaxis against graft-versus-host disease (GvHD) presented at the 2022 ASH Annual Meeting. The use of innovative agents and regimens, along with the conventional prophylactic approach of combining post-transplant cyclophosphamide and anti-thymocyte globulin, were discussed. The innovative agents and regimens highlighted in this review include abatacept, the first FDA-approved drug for acute GvHD prophylaxis; RGI-2001, which promotes the expansion of regulatory T cells; and cell therapies such as Orca-T and Orca-Q. These advancements provide promising strategies and options for GvHD prevention, offering hope for improved post-transplant patient outcomes in terms of survival rates.

Similar Items